Lu Xiangyi’s GL-12MS high-capacity refrigerated centrifuge, model 3 units, has been shipped to the Chengdu Pharmaceutical Factory.

Release time:

2019-04-30


Overview:

On the afternoon of April 30, Lu Xiangyi Centrifuge promptly packed and shipped a batch of GL-12MS high-capacity refrigerated centrifuges—each equipped with a 1000ml × 6-angle rotor—to a well-known national-class new drug biopharmaceutical high-tech enterprise in Chengdu, just before the May Day holiday. We hope these centrifuges will help this company achieve even greater improvements in production efficiency!

On the afternoon of April 30, Lu Xiangyi Centrifuge promptly packed and shipped a batch of GL-12MS large-capacity refrigerated centrifuges—each equipped with a 1000ml × 6-angle rotor—to Chengdu ahead of the May Day holiday. A well-known national Class I new drug biopharmaceutical high-tech enterprise hopes that this batch of centrifuges will help further enhance production efficiency and yield!

 GL-12M High-Capacity Refrigerated Centrifuge

With the development of the global economy, the growth in population, the deepening aging of society, and the increasing health awareness among residents, global demand for pharmaceuticals remains robust. In particular, the rapid growth of emerging markets has driven the sustained expansion of the global pharmaceutical market. On the domestic front, among China’s existing 189,000 drug approvals, more than 95% are generic drugs, while original-brand drugs are extremely scarce. Moreover, the efficacy of generic drugs has long been a subject of criticism. As early as 2017, China’s generic-drug market had already reached a scale of 500 billion yuan, and generic drugs continue to dominate the domestic pharmaceutical consumption market. In fact, among Chinese pharmaceutical companies, there’s always been a saying: The fundamental requirement for any drug is that it be safe and effective—but it’s better to be ineffective than unsafe. After all, the public’s eyes are sharp and discerning; they simply won’t buy drugs that aren’t effective.

Chengdu is located in a subtropical humid region with complex topography and diverse natural ecosystems, boasting an exceptionally rich biodiversity. This favorable environment has attracted numerous pharmaceutical companies to establish operations here. Well-known local pharmaceutical enterprises include Taiji Group, Sichuan Tiantai Mountain, Chengdu Haitong, Sichuan Kangjiale, and Sichuan Kelun. Recently, a major pharmaceutical manufacturer in Chengdu purchased three GL-12M large-capacity refrigerated centrifuges from Lushangyi, each equipped with 1000ml × 6-angle rotors. These centrifuges will be used to enhance the company’s R&D capabilities and production efficiency for new original drugs, thereby boosting the market share of both generic and original-brand drugs in China.

The GL-12MS high-capacity refrigerated centrifuge is widely used in fields such as clinical medicine, bioengineering, genetic engineering, and pharmaceutical manufacturing. This machine can reach a maximum rotor speed of 12,000 rpm and has a maximum capacity of up to 2,000 ml × 4. It is equipped with an integral food-grade silicone rubber seal that complies with GMP certification. Recently, Luxiangyi successfully designed and implemented a boring fixture, which significantly improves the precision of hole drilling for this high-capacity rotor. The testing results show that the clamping device achieves nearly zero errors in indexing accuracy, hole depth accuracy, and hole diameter accuracy. Furthermore, dynamic balancing tests indicate that the rotor’s unbalance is only 0.5 g. The application of this new technology not only helps pharmaceutical companies reduce costs but also enhances R&D efficiency and drug purity during both experimental and production processes.

 Packing for the GL-12M High-Capacity Refrigerated Centrifuge

Although China is currently a major producer of generic drugs, with an enormous variety and number of generic drug formulations, the quality of most domestically produced generic drugs still lags significantly behind that of originator drugs, making it difficult for them to capture market share from imported originator drugs. As a result, imported originator drugs continue to dominate the domestic market. However, as China’s pharmaceutical equipment and manufacturing technologies keep improving, the quality and efficacy of domestically produced drugs will also achieve a qualitative breakthrough, gradually narrowing the gap with imported originator drugs in the market and eventually replacing them altogether.

Shanghai Luxiangyi Centrifuge Instrument Co., Ltd. boasts a long history and strong technical expertise. Since its establishment, the company has been committed to promoting the innovative development of domestically produced centrifuges. Today, Shanghai Luxiangyi’s centrifuges have expanded into the international market, with exports reaching over 30 countries including the United States, Germany, the United Kingdom, Canada, and Thailand. While meeting domestic demand, the company has consistently focused on supporting the development of pharmaceutical enterprises in China. By continuously refining centrifuge manufacturing processes and enhancing product accuracy, Shanghai Luxiangyi provides valuable assistance to Chinese pharmaceutical companies throughout their journey of developing generic drugs and original research drugs.